Additionally, lefitolimod and cavrotolimod are TLR9 agonists being evaluated in solid tumors, while tilsotolimod and vidutolimod/CMP-001 are TLR9 agonists being tested in melanomas [29]. This evidence concerns the gene TLR9 and melanoma.